Clinical Trial Update: Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of iptacopan in C3 glomerulopathy is currently recruiting. The sponsor listed is Novartis Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: C3G | Phase 3 | Status: RECRUITING